Archive

Behind bogus promises of job creation and economic growth lies a dangerous agenda to shred social safety nets.

Your health shouldn’t be someone else’s wealth.

A Rolling Stone article by Andrew Perez cited Fred Ledley’s INET working paper on the NIH seed funding of pharmaceuticals.

Programs for expedited review may be preferentially reducing the development costs for conditions with lesser disease burden, potentially making investments in addressing the most significant disease burdens even less appealing and exacerbating the market failure further.

Do temporary economic shocks like the COVID-19 recession create lasting effects on the economy?

The discrepancy between technocratic rhetoric and economic facts is colossal.

Industry lobbyists vehemently oppose Medicare drug price negotiations. However, physician-scientist Fred Ledley and economist William Lazonick debunk their arguments.

How the dark side of consumer finance prioritizes profit over people.

The Uncertainty of Retirement in the New Economy

The “maximum fair price” for a drug must not only be equitable to those with unmet medical needs who may benefit from the use of the drug but also provide equitable returns on both public and private sector investments.

The empirical analysis of public sector investments and the health value created by the drugs selected for Medicare price negotiations provides a cost basis for the assessment of the maximum fair price.

James Galbraith flips the script on sanctions. How has Russia adapted?

Connecticut is the first state to fund and enact a baby bonds program, inspiring more states to create their own plans. Can it make a difference?

How can we better prepare for financial downturns?

Challenges And Emerging Perspectives